MET and hepatocellular carcinoma: Translational next steps include validating whether HO-1–high HCC exhibits reduced responsiveness to standard systemic regimens; testing rational combinations that co-target MET signalling and the HO-1/Nrf2 axis; and evaluating circulating HO-1 as a minimally invasive pharmacodynamic marker to monitor pathway suppression and resistance evolution.